Barclays on Global Biopharma Stocks: American Diabetes Association 2012: Highlights From GSK, LLY, SNY, NVO & JNJ
Get Alerts SNY Hot Sheet
Price: $49.36 --0%
Rating Summary:
7 Buy, 11 Hold, 3 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 1
Rating Summary:
7 Buy, 11 Hold, 3 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 1
Join SI Premium – FREE
Barclays on Global Biopharma stocks: American Diabetes Association (ADA) 2012
Analyst, C. Anthony Butler, said, "...the weekend highlighted potential new competition to incumbents in the diabetes space, particularly for insulins (Lilly's LY2605541), GLP-1s (Sanofi's lixisenatide, GlaxoSmithKline's albiglutide) and SGLT-2s (JNJ canagliflozin foremost). We reiterate our Overweight rating on Sanofi (NYSE: SNY) where expectations are low, although there could be significant volatility around release of the Lantus ORIGIN data, due imminently. We reiterate our Underweight rating on Novo Nordisk (NYSE: NVO), where expectations seem high. GlaxoSmithKline's (NYSE: GSK)(2-EW) abiglutide and Johnson & Johnson's (NYSE: JNJ)(1-OW) canagliflozin seem unlikely to materially move the needle for these big companies. Lilly's (NYSE: LLY) (2-EW) new insulin seems promising, although that stock seems driven more by expectations around new Alzheimer's agents."
Analyst, C. Anthony Butler, said, "...the weekend highlighted potential new competition to incumbents in the diabetes space, particularly for insulins (Lilly's LY2605541), GLP-1s (Sanofi's lixisenatide, GlaxoSmithKline's albiglutide) and SGLT-2s (JNJ canagliflozin foremost). We reiterate our Overweight rating on Sanofi (NYSE: SNY) where expectations are low, although there could be significant volatility around release of the Lantus ORIGIN data, due imminently. We reiterate our Underweight rating on Novo Nordisk (NYSE: NVO), where expectations seem high. GlaxoSmithKline's (NYSE: GSK)(2-EW) abiglutide and Johnson & Johnson's (NYSE: JNJ)(1-OW) canagliflozin seem unlikely to materially move the needle for these big companies. Lilly's (NYSE: LLY) (2-EW) new insulin seems promising, although that stock seems driven more by expectations around new Alzheimer's agents."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Range Resources (RRC) to Sector Perform
- WNS Limited (WNS) PT Lowered to $64 at TD Cowen
- Morgan Stanley Downgrades Envista Holdings Corp. (NVST) to Equalweight
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!